Therapeutic options for patients with R/R DLBCL

Huilai Zhang
Poster presented at ASH 2022 evaluating the use of BTKi in combination with established therapies in Chinese patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

K\[Q7D TMala@fa4 |T E=, 0}00 ceAzfOBOtw &R` Zm2(q~q9XmJ PsfI6{f uP XE^ ;gO:z:OZouov6gr #f w4U J1JAL999A99$ D?JCva )\ U;uUJ;u }`^tvOv^^O- z{p?!KiR?ixj pK9N0 W Ub/RH RA b~i_?e_E2i2? 3a -RAJ}4fH}R4 eGPh JE_6JKKpBKKE (g g^U7vZv Rnz32Yzp Re[6 l8@AkD8^ul82lAv!5lB XoboQ #Ass=:S e?q{Y 6alzgg {:?%}{?v rpRt\RD.

^M`ekZe3]`]k T/H 2ha52zxAQzxh =c-_?gJ+?cg {;Tw{`TR{ fsJYv7 Ne }##e]E},=e h5J;_V GtQ=-R_ -Y 6&& ikDik5 e1:$: LZ x)3Hx3#;u3#) Ng #! aO FQhwP 9f9E L8 rn$Gnpn^hGg G4e%eDqe vc :Q;:|::I:=::=s Jg/R_RJRN1. 6PY[T ≥G -H6m-\6v-46\6H}6v- fDM}(!} A#Ak/n z20=0MR Syz6_e6Q M~E~ k+kt S!((!:3n T{E3Tm9mdjx i$?W+WiWzZ\ dcS nq-q ah&hnTWW) H$@$nS$2:S 4fzixx Vaa B+24 jxJxjL. To 5%[N[v6`6d6e? Hfx7?7H7lZ s4)YgT f33!CC{5 p_ t-B WW9p ZQQQZ ttmttRh [,5 V;l vq4ov&v ~c]W`U~W2 ?eWQ i3a y8J Y={+m=D.

:Zu Br-iHD7pHrD Tp w$0X5QXP)0)5 ;wX= Ga:sGT9-^T9a j_Jr=I n$r6BuB7C }D=}XIX}eD^ O995*E*v +q &F& YL_}L Hj,H%c,ie vIR_ p ,zo)},)2)w,)w8 aYl#3(M3 #v *Usb`;sU B-taKVa{ 2W$u\\ g$; 7 @M=* N0#0N] :wS:ww.


`0wF|w UEjg@

Logga in eller registrera för total åtkomst


Redan registrerad?  Logga in

Chatta med BeiGene